The Biomarkers Oncologists Need to Know for Personalized Cancer Care in 2019

In this online CME-certified program, experts discuss how to leverage 10 key clinical biomarkers to enhance patient care across multiple cancers. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium in Chicago and then download the biomarker summary resources to learn more about how to use biomarkers to select optimal therapy for your patients with cancer.
John L. Marshall, MD
Program Director
Todd M. Bauer, MD
Justin F. Gainor, MD
Giuseppe Giaccone, MD, PhD
Axel Grothey Headshot
Axel Grothey, MD
Michael J. Pishvaian, MD, PhD
David R. Spigel, MD

Downloadable Slidesets

In this downloadable slideset, John L. Marshall, MD, discusses the current data on using MMRd/MSI status to select patients for treatment with immune checkpoint inhibitors across all solid tumors.

John L. Marshall, MD
Program Director
Released: May 31, 2019

In this downloadable slideset, Giuseppe Giaccone, MD, PhD, discusses the current data on using PD-L1 status to select patients for treatment with immune checkpoint inhibitors in solid tumors.

Giuseppe Giaccone, MD, PhD Released: May 31, 2019

In this downloadable slideset, Michael J. Pishvaian, MD, PhD, discusses the current data on using BRCA mutation status to identify patients for treatment with PARP inhibitors in select solid tumors.

Michael J. Pishvaian, MD, PhD Released: May 31, 2019

In this downloadable slideset, Axel Grothey, MD, discusses the current data on optimal treatment options for patients with cancer and BRAF, MAPK, or HER2 alterations.

Axel Grothey Headshot Axel Grothey, MD Released: May 31, 2019

In this downloadable slideset, Todd M. Bauer, MD, discusses the current data on optimal treatment options for patients with NTRK, ROS1, FGFR, or RET altered tumors.

Todd M. Bauer, MD Released: June 3, 2019

ClinicalThought

Are you up to date on the latest information on targeting RET alterations in patients with NSCLC and other malignancies?

Justin F. Gainor, MD Released: July 25, 2019

Downloadable Biomarker Summary Resources

Gain insights on the clinical role of BRCA1/2 mutations with this downloadable PDF summarizing genetic risk evaluation, approved therapies, and companion diagnostics for breast, ovarian, pancreatic, and prostate cancers.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Consult this PDF resource to gain clinical insights on recently approved indications and emerging biomarkers in multiple malignancies, including PIK3CA, PDFGRα, KIT, MET, and KRASG12C.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Gain clinical insights on FGFR alterations in multiple malignancies, including FDA-approved and investigational agents, and current testing approaches with this PDF resource.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Review this PDF resource for clinical insights on the use of HER2 alterations in various malignancies, along with current FDA-approved indications and companion diagnostics in breast cancer and gastric/gastroesophageal junction cancer.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Download this PDF featuring clinical insights, approved therapies, and available assays for MSI-high/MMR-deficient colorectal cancer and other solid tumors.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Gain clinical insights on FDA-approved immunotherapy indications and complementary diagnostics for PD-L1 in multiple malignancies with this PDF resource.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Download this PDF resource for clinical insights on BRAF mutations, from types of mutations to FDA-approved agents and companion diagnostics, in multiple solid tumors.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Download this PDF clinical resource reviewing investigational RET inhibitors and testing strategies for RET alterations in thyroid cancer, NSCLC, and other malignancies.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Get up to date on the clinical role of ROS1 rearrangements in nonsquamous NSCLC, including FDA-approved targeted therapies and diagnostic methods, with this downloadable PDF resource.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

Review this PDF resource summarizing FDA-approved and investigational TRK inhibitors and testing platforms for NTRK fusions in multiple malignancies.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD David R. Spigel, MD
Released: May 31, 2019

On-Demand Webcast

Watch this on-demand Webcast from our live symposium to review the latest clinical data and expert perspectives on using biomarkers to select therapy for your patients with solid tumors.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Giuseppe Giaccone, MD, PhD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 11, 2019 Expiration: July 10, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Array BioPharma
Bayer Healthcare Pharmaceuticals Inc.
Blueprint Medicines
Celgene Corporation
Foundation Medicine, Inc.
Genentech
Loxo Oncology
Merck & Co., Inc.
Puma Biotechnology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?